Value creation: Are pure-plays better than hybrids?

In this research note, we consider the value and merits of using a pure-play business model (i.e. biotech R&D pipeline, or cash generating services business) against the hybrid approach. Several case studies from the market suggest there may be greater value in focus.

Read the full note here:

Value creation- Pure plays vs hybrids 170610

This note was written by Raman Minhas and Olivier Koechlin. Raman Minhas is CEO of ATPBio, a strategy and transaction consultancy focused on life sciences. Olivier Koechlin is a Managing Partner at Fraser Finance, a specialist investment bank focused on life sciences and TMT.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s